Innovative Therapeutics in Oncology and Neuroscience
Our Vision - Leveraging Our Strength in China and Scientific Expertise to
Become A Global Biopharma Leader
zaiLab
Key Market
Trends
Pipeline of late-
stage potential
FIC / BIC assets
Substantial market
potential with
significant unmet
needs
Large patient pool with an
aging population in China
Strong commercial
infrastructure &
execution in China
with high synergy
Pricing reflects
clinical value of
innovative drugs
in NRDL
"Price driven" to "Clinical
value-oriented"
Global leaders with
decades of R&D
experience to
identify and develop
innovative drugs
Policies fostering
innovative drug
development
Accelerating regulatory
pathway
Expanding our
innovative global
drug pipeline
China as a rising
center of
innovation for
global market
Increasing sourcing of
innovation from China
3
Abbreviations: first-in-class (FIC), best-in-class (BIC), China's national reimbursement drug list (NRDL).
zaiLabView entire presentation